News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Iran Denies Direct Talks; Oil Price Back Above $100; Nasdaq 100 Rule Change May Open Door for SpaceX (March 31, 2026)2Bitcoin data points to ‘rare’ trading setup for relief rally to $71K3Iran's Potential Blockade of the Strait of Hormuz: Approaching April 6 and Growing Market Anxiety
onsemi’s 4.6% Decline: $399 Million Transaction Compared to $10 Billion Market Value Decrease
101 finance·2026/03/31 13:06
Market Strategist to XRP Holders: Be Very Careful the Next 2 to 3 Days. Here’s why
TimesTabloid·2026/03/31 13:06
Palantir's Oversold Bounce Faces Bearish Supply at Key MAs as Valuation Trap Looms
101 finance·2026/03/31 13:03
TD Cowen's Hold at $82 Signals Sector Reassessment—Is Sezzle's Growth Already Priced In?
101 finance·2026/03/31 13:03
Settlement Velocity: An Examination of T+1’s Effects on the Market
101 finance·2026/03/31 13:03
Chainalysis introduces 'blockchain intelligence agents' trained on millions of investigations
The Block·2026/03/31 13:03
Flash
13:23
Eightco Holdings Inc. recently announced its assets under management, with a total holding value reaching as high as 326 millions USD.This portfolio includes nearly 280 million Worldcoin (WLD) and more than 11,000 Ethereum (ETH), demonstrating the company's significant positioning in the cryptocurrency sector.
13:16
Eli Lilly plans to acquire biotechnology company Centessa for up to $7.8 billions.Luo Tonghui March 31｜Eli Lilly announced that it has reached a definitive agreement to acquire Centessa Pharmaceuticals, a clinical-stage biotechnology company, with a total transaction value of up to $7.8 billion. Eli Lilly will acquire Centessa shares for $38 in cash per share, representing a 40.5% premium over its volume-weighted average price on the 30th; if regulatory milestones are achieved in the future, each share may receive up to an additional $9. This acquisition will grant Eli Lilly ownership of Centessa's orexin receptor 2 (OX2R) agonist product line, including cleminorexton, which is considered a potential best-in-class therapy for sleep-wake disorders such as narcolepsy type 1 and type 2 as well as idiopathic hypersomnia. The portfolio also includes several early-stage candidate drugs with potential in the broader neurological and neuropsychiatric disease fields.
13:07
Galaxy Digital announces that its GalaxyOne platform has launched SOL staking functionalityJinse Finance reported that on March 31, the Nasdaq-listed crypto financial services group Galaxy Digital announced that its fintech platform GalaxyOne has launched SOL staking functionality. This service is open to eligible customers in more than 40 states and regions in the United States, and all SOL staked on GalaxyOne will be delegated to the Galaxy Digital validator.
News